- Home
- BLNK vs DCTH Comparison
BLNK vs DCTH Comparison
Compare BLNK & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- DCTH
- Stock Information
- Founded
- BLNK 2009
- DCTH 1988
- Country
- BLNK United States
- DCTH United States
- Employees
- BLNK N/A
- DCTH N/A
- Industry
- BLNK Industrial Specialties
- DCTH Medical/Dental Instruments
- Sector
- BLNK Consumer Discretionary
- DCTH Health Care
- Exchange
- BLNK Nasdaq
- DCTH Nasdaq
- Market Cap
- BLNK 129.3M
- DCTH 388.3M
- IPO Year
- BLNK N/A
- DCTH N/A
- Fundamental
- Price
- BLNK $1.41
- DCTH $11.49
- Analyst Decision
- BLNK Buy
- DCTH Strong Buy
- Analyst Count
- BLNK 8
- DCTH 4
- Target Price
- BLNK $2.54
- DCTH $24.50
- AVG Volume (30 Days)
- BLNK 3.4M
- DCTH 493.0K
- Earning Date
- BLNK 11-06-2025
- DCTH 11-07-2025
- Dividend Yield
- BLNK N/A
- DCTH N/A
- EPS Growth
- BLNK N/A
- DCTH N/A
- EPS
- BLNK N/A
- DCTH 0.06
- Revenue
- BLNK $104,788,000.00
- DCTH $70,240,000.00
- Revenue This Year
- BLNK N/A
- DCTH $159.22
- Revenue Next Year
- BLNK $19.30
- DCTH $42.78
- P/E Ratio
- BLNK N/A
- DCTH $201.97
- Revenue Growth
- BLNK N/A
- DCTH 491.35
- 52 Week Low
- BLNK $0.63
- DCTH $8.08
- 52 Week High
- BLNK $2.32
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- BLNK 72.73
- DCTH 56.13
- Support Level
- BLNK $1.28
- DCTH $10.61
- Resistance Level
- BLNK $1.44
- DCTH $11.38
- Average True Range (ATR)
- BLNK 0.10
- DCTH 0.46
- MACD
- BLNK 0.03
- DCTH 0.04
- Stochastic Oscillator
- BLNK 91.86
- DCTH 67.67
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.